Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:L01XE48
|
| gptkbp:brand |
gptkb:Alunbrig
|
| gptkbp:CASNumber |
1197953-54-0
|
| gptkbp:developer |
gptkb:Ariad_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
25 hours
|
| gptkbp:hasMolecularFormula |
C29H39N7O2P
|
| https://www.w3.org/2000/01/rdf-schema#label |
brigatinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
ALK inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:proteinBinding |
66%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue hypertension cough elevated creatine phosphokinase |
| gptkbp:target |
gptkb:anaplastic_lymphoma_kinase
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:ALK_rearrangement
|
| gptkbp:bfsLayer |
5
|